News Quantified

DMAC – diamedica therapeutics inc. (US:NASDAQ)

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA [Yahoo! Finance]

12/18

08:45 am

dmac

Low

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.

DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]

DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}